| Dr Ali Ibrahim Gardezi, MD | |
|
3034 Fish Hatchery Rd, Fitchburg, WI 53713-3125 | |
| (608) 270-5656 | |
| (608) 270-5602 |
| Full Name | Dr Ali Ibrahim Gardezi |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 19 Years |
| Location | 3034 Fish Hatchery Rd, Fitchburg, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356506794 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 61896 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wi Dialysis Inc - Fitchburg Clinic | Madison, WI | Dialysis facility |
| Total Renal Care Inc | Wisconsin dells, WI | Dialysis facility |
| Meriter Hospital | Madison, WI | Hospital |
| University Of Wi Hospitals & Clinics Authority | Madison, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Wisconsin Medical Foundation Inc | 6608785464 | 2164 |
News Archive
A new study published in January 2020 in the journal JAMA Network Open shows that government regulations restricting the use of e-cigarettes may be instrumental in reducing the use of these devices by American adults.
The American College of Chest Physicians recently released new clinical guidelines on the Diagnosis and Evaluation of Hypersensitivity Pneumonitis (HP).
A new report from an ER physician group measured "access to care, quality and patient safety, liability, injury prevention and disaster preparedness," offering a snapshot of national and state policies affecting emergency medicine.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.
Abbott announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas (pancreatectomy). Prior to this FDA approval, dosing guidance for medications such as CREON was based on patients with cystic fibrosis.
› Verified 5 days ago
| Entity Name | University Of Wisconsin Medical Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598784555 PECOS PAC ID: 6608785464 Enrollment ID: O20031111000435 |
News Archive
A new study published in January 2020 in the journal JAMA Network Open shows that government regulations restricting the use of e-cigarettes may be instrumental in reducing the use of these devices by American adults.
The American College of Chest Physicians recently released new clinical guidelines on the Diagnosis and Evaluation of Hypersensitivity Pneumonitis (HP).
A new report from an ER physician group measured "access to care, quality and patient safety, liability, injury prevention and disaster preparedness," offering a snapshot of national and state policies affecting emergency medicine.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.
Abbott announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas (pancreatectomy). Prior to this FDA approval, dosing guidance for medications such as CREON was based on patients with cystic fibrosis.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ali Ibrahim Gardezi, MD 7974 Uw Health Ct, Middleton, WI 53562-5531 Ph: () - | Dr Ali Ibrahim Gardezi, MD 3034 Fish Hatchery Rd, Fitchburg, WI 53713-3125 Ph: (608) 270-5656 |
News Archive
A new study published in January 2020 in the journal JAMA Network Open shows that government regulations restricting the use of e-cigarettes may be instrumental in reducing the use of these devices by American adults.
The American College of Chest Physicians recently released new clinical guidelines on the Diagnosis and Evaluation of Hypersensitivity Pneumonitis (HP).
A new report from an ER physician group measured "access to care, quality and patient safety, liability, injury prevention and disaster preparedness," offering a snapshot of national and state policies affecting emergency medicine.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.
Abbott announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas (pancreatectomy). Prior to this FDA approval, dosing guidance for medications such as CREON was based on patients with cystic fibrosis.
› Verified 5 days ago
Dr. Sarah E Panzer, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3034 Fish Hatchery Rd, Fitchburg, WI 53713 Phone: 608-270-5600 | |
Jacalyn A Nelson, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2844 Index Rd, Fitchburg, WI 53713 Phone: 608-229-7979 Fax: 608-229-8110 | |
Rachael Ziska, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3051 Cahill Main, Fitchburg, WI 53711 Phone: 608-661-7200 | |
Laura Maursetter, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3034 Fish Hatchery Rd, Fitchburg, WI 53713 Phone: 608-270-5656 | |
Dr. Daniel Joel Mcculley, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 5543 E Cheryl Pkwy, Fitchburg, WI 53711 Phone: 608-263-7740 Fax: 608-262-6048 | |
Dr. Don A Harden, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 2844 Index Rd, Fitchburg, WI 53713 Phone: 608-229-7979 Fax: 608-229-8110 | |
Uzoamaka E Achufusi, MBBS Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3034 Fish Hatchery Rd, Fitchburg, WI 53713 Phone: 608-270-5656 |